FINWIRES · TerminalLIVE
FINWIRES

Zhejiang Hisun Pharmaceutical Subsidiary Gets China Nod for Anti-Parasite Drug for Cats

By

Zhejiang Hisun Pharmaceutical (SHA:600267) subsidiary Zhejiang Hisun Animal Health Products received a veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for its fipronil, praziquantel, and moxidectin compound drug, according to a Tuesday disclosure to the Shanghai bourse.

The drug helps prevent parasitic infections in cats, including fleas and ticks, heartworm, and gastrointestinal nematodes, and as an adjunctive treatment for flea allergy dermatitis, the filing said.

Related Articles

Asia

Majestic Dragon Aerotech Appoints Marketing Chief

Majestic Dragon Aerotech (HKG:0918) has appointed Zhang Chen as the company's chief marketing officer, according to a Monday bourse filing.Zhang has over 10 years of experience in real estate development and in managing hotel operations and fire safety systems. His appointment will be effective Dec. 7.

HKG:0918
Asia

HRnetGroup Gets SGX-ST Preliminary Nod for Share Listing

HRnetGroup (SGX:CHZ) has received in-principle approval from the Singapore Exchange Securities Trading (SGX-ST) for the listing and quotation of 241,527 shares to be transferred to certain employees and executive director.The approval is subject to the company complying with SGX-ST listing requirements, including obtaining specific shareholders' approval where applicable, according to a Monday Singapore Exchange filing.The company will make the necessary announcement once the shares are transferred.

SGX:CHZ
Asia

Sequoia Financial Group Ex-Boss Faces 10-Year ASIC Ban From Financial Services Roles

Sequoia Financial Group (ASX:SEQ) former Chief Executive Garry Crole has been banned by the Australian Securities and Investments Commission (ASIC) for 10 years from performing any function involved in carrying on a financial services business as a director or responsible manager, according to a Tuesday statement by ASIC.The regulator said Crole failed to adequately respond to serious concerns about the financial advice model used by former Interprac-authorized representatives, who advised thousands of clients to invest superannuation in the now-collapsed First Guardian and Shield Master Funds.The company did not immediately respond to anemail request for comment.

ASX:SEQ